Stem cell transplantation and MBL replacement therapy

Current Stem Cell Research and Therapy

Volumn 3, Issue 2, 2008, Pages 85-87

  Kilpatrick, David C ^a  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

Mannan binding lectin; Mannose binding lectin; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOCONJUGATE; MANNOSE BINDING LECTIN; MANNOSE BINDING LECTIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CELL MATURATION; CELL TYPE; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; DONOR; GENE MUTATION; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; INFECTION RISK; INFECTION SENSITIVITY; LEUKOCYTE; LIVER TRANSPLANTATION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; REMISSION; REVIEW; SOLID TUMOR; STEM CELL TRANSPLANTATION;

COMMUNICABLE DISEASES; HUMANS; MANNOSE-BINDING LECTIN; STEM CELL TRANSPLANTATION;

EID: 47749112944     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488808784223069     Document Type: Review

References (20)

1. Wallis R, Lynch NJ. In: Kilpatrick D Ed, Collagen-related lectins in innate immunity. Trivandrum, Research Signpost 2007; 33-56.
2. Kilpatrick DC. Mannan-binding lectin: clinical significance and applications. Biochim Biophys Acta 2002; 1572: 401-413.
3. Kilpatrick DC. In: Kilpatrick D Ed, Collagen-related lectins in innate immunity. Trivandrum, Research Signpost 2007; 57-84.
4. Vekemans M, Robinson J, Georgala A, et al. Low mannose-binding lectin concentration is associated with severe infection in patients with haematological cancer who are undergoing chemotherapy. Clin Inf Dis 2007; 44: 1593-1601.
5. Schlapbach LJ, Aebi C, Otth M, et al. Serum levels of mannose-binding lectin and risk of fever in neutropenic pediatric cancer patients. Pediatr Blood Cancer 2007; 49: 11-16.
6. Shi L, Takahashi K, Dundee J, et al. Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J Exp Med 2004; 199: 1379-1390.
7. Mullighan CG, Heatley S, Doherty K, et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 2002; 99: 3524-3529.
8. Granell M, Urbano-Ispizua A, Suarez B, et al. Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol 2006; 34: 1435-1441.
9. Downing I, Koch C, Kilpatrick DC. Immature dendritic cells possess a sugar-sensitive receptor for human mannan-binding lectin. Immunology 2003; 109: 360-364.
10. Sorensen CM, Hansen TK, Steffensen R, Jensenius JC, Thiel S. Hormonal regulation of mannan-binding lectin synthesis in hepatocytes. Clin Exp Immunol 2006; 145: 173-182.
11. Seyfarth J, Garred P, Madsen, HO. Extra-hepatic transcription of the human mannose-binding lectin gene (mbl2) and the MBL-associated serine protease 1-3 genes. Mol Immunol 2006; 43: 962-971.
12. Kilpatrick DC, Stewart K, Allan EK, McLintock LA, Holyoake TL, TurnerML. Successful haemopoietic stem cell transplantation does not correct mannan-binding lectin deficiency. Bone Marrow Trans 2005; 35: 179-181.
13. Bouwman LH, Roos A, Terpstra OT et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterol 2005; 129: 408-414.
14. de Carvalho EG,da Rosa Utiyama SR, da Silva Kotze L, de Messias Reason IT. Serum mannan-binding lectin levels in patients with celiac disease: an analysis of clinical and autoimmune features. Dig Dis Sci 2007; 52: 2145-2151.
15. Downing I, MacDonald SL, Turner ML, Kilpatrick DC. Detection of an autologous ligand for mannan-binding lectin on human B lymphocytes. Scand J Immunol 2005; 62: 507-514.
16. Kilpatrick DC, Downing I, MacDonald SL, Turner ML. MBL really binds to healthy human cells! Scand J Immunol 2007; 66: 599-600.
17. Valdimarsson H, Vikingsdottir T, Bang P, et al. Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study. Scand J Immunol 2004; 59: 97-102.
18. Petersen KA, Matthiesen F, Agger T, et al. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J Clin Immunol 2006; 26: 465-475.
19. Valdimarsson H, Stefansson M, Vikingsdottir T, et al. Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans. Scand J Immunol 1998; 48: 116-123.
20. Valdimarsson H. Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans. Biochem Soc Trans 2003; 31: 768-769.